Version 2.5.2.0

Abstract

Grant Number:	2P50CA058207-090011
Project Title:	PREDICTORS OF RECURRENCE IN WOMEN WITH DCIS

PI Information:	Name	Email	Title
	KERLIKOWSKE, KARLA M.	karla.kerlikowske@ucsf.edu

Abstract: We propose to define the risk of disease recurrence or progression by clinical and histopathologic characteristics and molecular and genetic markers in a population-based study of women with ductal carcinoma in situ (DCIS) of the breast. Three study cohorts will be evaluated: (1) a population-based cohort of 1,744 women diagnosed with DCIS from 1983-96, identified by the Northern California Surveillance, Epidemiology, and End Results Program, who underwent lumpectomy alone for treatment, (2) women diagnosed with DCIS whose tissue has been collected at UCSF for the Breast Oncology Program database (N = 457), and (3) a subset of the 1,310 women initially diagnosed with DCIS who underwent lumpectomy and radiation therapy in the NSABPB-17 and NSABPB-24 trials. We will determine the risk of recurrence or progression of DCIS and/or invasive cancer in women treated by lumpectomy alone according to: (1) nuclear grade, necrosis type, margin width, and established molecular markers (p53, erbB-2, ER, PgR, and Ki67); (2) candidate molecular markers of cell cycle dysregulation (Cyclin D1, p16 methylation), tumor invasiveness (e.g., VEGF, factor VI11 related antigen, Cox-2), and stromal-breast epithelium interactions (e.g., uPA and related proteins, E-cadherin, beta 1integrin); and (3) a subset of chromosomal alterations detected by array-based comparative genomic hybridization. In addition, to validate out findings, we will evaluate women that underwent lumpectomy and radiation therapy to assess that the same measures that predict recurrence among women treated by lumpectomy alone also predict recurrence among women who received adjuvant radiotherapy (Group 3). The results of these studies will be used to develop a risk assessment tool based on measures that have been found to be independently associated with recurrence in a multivariate model. The risk assessment tool will estimate the risk of recurrence for an individual woman as a function of her clinical (e.g., age at diagnosis, menopause status) and histopathology (e.g., nuclear grade, margin width) information, established molecular markers (e.g., ER status, Ki67), and candidate markers.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
breast neoplasm, genetic marker, longitudinal human study, metastasis, neoplasm /cancer relapse /recurrence, neoplasm /cancer therapy, pathologic process, prognosis
chromosome aberration, combination cancer therapy, human population study, molecular pathology, neoplasm /cancer chemotherapy, neoplasm /cancer classification /staging, neoplasm /cancer epidemiology, neoplasm /cancer radiation therapy, neoplasm /cancer surgery, women's health
clinical research, comparative genomic hybridization, data collection methodology /evaluation, histopathology, human subject, statistics /biometry

Institution:	UNIVERSITY OF CALIFORNIA SAN FRANCISCO
	3333 California St., Ste 315
	SAN FRANCISCO, CA 941430962
Fiscal Year:	2003
Department:
Project Start:	01-JUL-2003
Project End:	30-NOV-2007
ICD:	NATIONAL CANCER INSTITUTE
IRG:	ZCA1

---